Anjan Chatterjee MD Mph MBA
About Anjan Chatterjee MD Mph MBA
Anjan Chatterjee, MD, MPH, MBA, serves as the Senior Vice President and Global Head of Medical Affairs, HEOR, RWE, and Pharmaco-epidemiology at Insmed Incorporated. He has extensive experience in the pharmaceutical industry, having held leadership roles at Pfizer Pharmaceuticals, Boehringer Ingelheim, and VR1 Inc.
Current Role at Insmed
Anjan Chatterjee serves as the Senior Vice President and Global Head of Medical Affairs, HEOR, RWE, and Pharmaco-epidemiology at Insmed Incorporated. He has held this position since 2019, contributing to the company's strategic direction in medical affairs. His role involves leading global medical affairs teams across the US, EU, and Japan, with a focus on health economics and outcomes research, real-world evidence, and pharmaco-epidemiology. Chatterjee is responsible for building a global Real World Evidence organization to enhance market access for medicines upon launch and thereafter.
Professional Experience
Chatterjee has extensive experience in the pharmaceutical industry, having worked in various senior roles. He was a Senior Medical Director at Pfizer Pharmaceuticals from 2008 to 2012, where he led multiple initiatives in medical affairs. He also served as the CEO of VR1 Inc from 2012 to 2016. At Boehringer Ingelheim, he held several positions including Corporate Vice President and Executive Director, focusing on therapeutic areas such as ophthalmology and immunology. His career also includes a role as Associate Medical Director at Merck Research Labs.
Educational Background
Anjan Chatterjee has a robust educational background in medicine and public health. He earned his MD from Delhi University, studying from 1984 to 1990. He furthered his education with a Master of Public Health (MPH) in Epidemiology and Biostatistics from Columbia University Mailman School of Public Health, completed in 2004. Chatterjee also holds an MBA from Columbia Business School, where he studied Accounting, Finance, and Economics from 2009 to 2011. Additionally, he completed a Movement Disorders Fellowship at Columbia University Vagelos College of Physicians and Surgeons.
Regulatory Interaction and Drug Development
Chatterjee has substantial experience interacting with regulatory bodies, including the US FDA, CHMP (EMEA), PMDA (Japan), and SFDA (China). His expertise extends to managing drug development processes from Phase 1B through FDA submission and approval. He has successfully launched drugs in major markets, including the US, EU, Japan, and China, demonstrating his capability in navigating complex regulatory landscapes and ensuring compliance throughout the drug development lifecycle.